3 ASX shares I dream of owning at the right price

These companies look incredibly appealing in my eyes. What price would it take for me to dive in?

| More on:
a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are many ASX shares vying for a position in my portfolio at any single point in time. Companies that exhibit impressive revenue growth, sell incredibly valuable products/services, and are leaders in their fields.

However, as amazing as these businesses might be, many fail to meet one of the most important hurdles … the right price. More specifically, a price that is accommodative to the errors we all will inevitably make from time to time as investors.

The margin of safety is one of the most important investing principles, yet I rarely hear it discussed. This is despite it being one of the few things that can be controlled as a small shareholder. Several years of returns can be engulfed by paying too high of a price for even quality companies.

Below are three ASX shares that I believe are exceptional businesses, but trade on exceptionally high valuations.

I'd buy these ASX shares if the price was right

Objective Corporation Limited (ASX: OCL)

Objective Corp is possibly my favourite company on this list, making it into my top 10 picks for 2023. The company provides a broad range of software solutions to both the public and private sectors.

Thirty-six years on from its inception and Objective Corp is still delivering 20% year-on-year earnings growth. Another enticing trait is the company's rock-solid balance sheet, with no debt and $63.8 million in cash. Not to mention it is founder-led by Tony Walls, who holds an ownership stake of more than 65% in the company.

Unfortunately, the price-to-earnings (P/E) ratio of around 73 times offers little in the way of a margin of safety. Even if Objective's revenue grows at 20% over the next five years, most of that appears to be priced in. I'd happily add this ASX share to my portfolio if the price was more in the ballpark of $8 to $9.

Currently, it trades at $14.80.

Polynovo Ltd (ASX: PNV)

This is a company I had held previously in my portfolio but decided to remove it due to its deteriorating balance sheet.

Polynovo leverages its proprietary polymer technology for wound treatment and burns. Impressively, the company's revenue has been growing at a 62% clip in the last year, reaching $41.9 million. Though, expansion to new markets and customers is still in the early stages.

Furthermore, Polynovo has recently undertaken a $30 million institutional placement, fortifying its balance sheet once more. Though, the business is still loss-making.

The rapid revenue growth is alluring, but the industry can be competitive. For example, Avita Medical Inc (ASX: AVH) offers a burn treatment of its own that comes in a spray-on form.

Given that Polynovo is yet to prove its profitability, I'm personally holding out for a share price below $1.30. At present, shares in this ASX medical company are fetching $2.50 apiece.

CSL Limited (ASX: CSL)

I'd assume I'm not alone in dreaming of owning a piece of this Australian biotech beast.

CSL is a company that probably needs no introduction. Its expansive portfolio of intellectual property puts it on the world stage of healthcare expertise — covering antibodies, clotting agents, and HPV and flu vaccines.

The company's medical technology is hard to replicate and is usually protected by law, leading to profit margins above 20%. Additionally, the management team has demonstrated exceptional ability in making accretive acquisitions over the years.

Nonetheless, at an earnings multiple of 39 times FY25 forecast earnings for the company, CSL's valuation is a bit difficult for me to swallow. I'd personally love to add CSL to my portfolio at a price below $200 compared to its current $295.

Should you invest $1,000 in Dexus Convenience Retail Reit right now?

Before you buy Dexus Convenience Retail Reit shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Dexus Convenience Retail Reit wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Avita Medical, CSL, Objective, and PolyNovo. The Motley Fool Australia has recommended Avita Medical. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

A businessman hugs his computer and smiles.
Opinions

2 ASX 300 shares I plan to own forever

Both of these businesses have good ultra-long-term outlooks.

Read more »

Close-up of a business man's hand stacking gold coins into piles on a desktop.
Opinions

If I had a big cash pile like Warren Buffett, here's how I'd spend it in 2025

I'd put Buffett's billions to work straight away.

Read more »

Concept image of a businessman riding a bull on an upwards arrow.
Opinions

Why I'm bullish on the Guzman Y Gomez share price for the long-term

The business is delivering spicy growth.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
Opinions

2 ASX shares I'd buy if the ASX crashes again

I think the best opportunities can be found when the market falls.

Read more »

A man and woman sit at a desk staring intently at a laptop screen with papers next to them.
Opinions

Where I'd invest $5,000 in ASX 300 shares right now

These stocks look like excellent investments today.

Read more »

Man smiling at a laptop because of a rising share price.
Opinions

My 2 favourite ASX sectors to invest in

Finding your groove can help your investing success.

Read more »

Legendary share market investing expert and owner of Berkshire Hathaway Warren Buffett
Opinions

3 things I learned from Warren Buffett being the CEO of Berkshire Hathaway

The Oracle from Omaha is in his last year as CEO.

Read more »

Man looking happy and excited as he looks at his mobile phone.
Opinions

Why I think this small ASX dividend share is a great buy today

This small business offers a lot of what I like for passive income.

Read more »